<SEC-DOCUMENT>0001193125-16-675121.txt : 20160808
<SEC-HEADER>0001193125-16-675121.hdr.sgml : 20160808
<ACCEPTANCE-DATETIME>20160808161503
ACCESSION NUMBER:		0001193125-16-675121
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20160808
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20160808
DATE AS OF CHANGE:		20160808

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARDELYX, INC.
		CENTRAL INDEX KEY:			0001437402
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36485
		FILM NUMBER:		161814330

	BUSINESS ADDRESS:	
		STREET 1:		34175 ARDENWOOD BLVD.
		CITY:			FREMONT
		STATE:			CA
		ZIP:			94555
		BUSINESS PHONE:		510-745-7047

	MAIL ADDRESS:	
		STREET 1:		34175 ARDENWOOD BLVD.
		CITY:			FREMONT
		STATE:			CA
		ZIP:			94555

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NTERYX INC
		DATE OF NAME CHANGE:	20080611
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d208065d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 8-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant
to Section&nbsp;13 or 15(d) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): August&nbsp;8, 2016 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>ARDELYX, INC. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact
name of registrant as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>001-36485</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>26-1303944</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification Number)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>34175 Ardenwood Blvd., Suite 200 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Fremont, CA 94555 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive offices, including Zip Code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s telephone number, including area code: (510)&nbsp;745-1700 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;2.02 Results of Operations and Financial Condition. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&nbsp;8, 2016, Ardelyx, Inc. (the &#147;Company&#148;) announced its financial results for the quarter ended June&nbsp;30, 2016. The full text of the
press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information furnished under
this Item&nbsp;2.02 shall not be considered &#147;filed&#148; under the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference into any future filing under the Securities Act of 1933, as amended, or under&nbsp;the
Securities Exchange Act of 1934, as amended, unless the Company expressly sets forth in such future filing that such information is to be considered &#147;filed&#148; or incorporated by reference therein. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;9.01 Financial Statements and Exhibits. </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(d)</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Exhibits. </B></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:37.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Exhibit&nbsp;No.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:37.25pt; font-size:8pt; font-family:Times New Roman">Description</P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press release of Ardelyx, Inc.</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: August&nbsp;8, 2016</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">ARDELYX, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Mark Kaufmann</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Mark Kaufmann</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Financial Officer</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:37.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Exhibit&nbsp;No.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:37.25pt; font-size:8pt; font-family:Times New Roman">Description</P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press release of Ardelyx, Inc.</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d208065dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ROWSPAN="4" ALIGN="center">


<IMG SRC="g208065g77r46.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">34175 Ardenwood Blvd</TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fremont, CA 94555</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(510) 745-1700 &#150; Tele</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(510) 745-0493 &#150; Fax</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">www.ardelyx.com</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Ardelyx Reports Second Quarter 2016 Financial Results </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>&#151; Results from the First Phase 3 trial for Tenapanor for the Treatment of Hyperphosphatemia in </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Patients with ESRD Expected Q1 2017&#151; </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>&#151; Ardelyx&#146;s Proprietary Potassium Binder, RDX227675, Obtains Notification of Allowance for </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Composition of Matter Claims &#151; </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Conference Call and Webcast Today at 4:30 p.m. ET </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">FREMONT, Calif., August&nbsp;8, 2016 /PRNewswire/ &#151;&nbsp;Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on
gastrointestinal and cardio-renal diseases, today announced financial results for the second quarter ended June&nbsp;30, 2016. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;2016 continues to be
a momentous year,&#148; said Mike Raab, President and Chief Executive Officer of Ardelyx. &#147;With the completion of our recently announced $110 million private placement, we have raised net proceeds of over $190 million in 2016. Now that we have
strengthened our balance sheet with sufficient capital to support the company through our receipt of critical clinical milestones in 2017, our primary focus is the execution of our late-stage clinical programs and advancement of the company towards
commercialization. During 2017, all three of our late-stage programs will generate important clinical data. This includes currently expected results in the first quarter of next year from our first Phase 3 trial of tenapanor for the treatment of
hyperphosphatemia in ESRD patients on dialysis. We believe that tenapanor has the potential to be a truly important development for the treatment of hyperphosphatemia in these patients. We also currently expect results in the first half of 2017 from
our onset-of-action trial for RDX227675 in patients with hyperkalemia. Finally, we currently expect results from both Phase 3 clinical trials of tenapanor for IBS-C, with T3MPO-1 mid-year and T3MPO-2 by the end of 2017.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recent Highlights </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Announced positive End-of-Phase 2 (EoP2) meeting with the U.S. Food and Drug Administration (FDA) for tenapanor for the treatment of hyperphosphatemia in end-stage renal disease (ESRD) patients on dialysis. As a result
of the meeting, the currently ongoing clinical trial will now serve as the first of two Phase 3 registration trials to support the filing of a new drug application (NDA); </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Once-daily-dosing of RDX227675 demonstrated effects equal to two or three times daily dosing; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Strengthened the Board with the addition of industry veteran, Robert Bazemore, to the Company&#146;s Board of Directors. Mr.&nbsp;Bazemore currently serves as President and Chief Executive Officer of Epizyme, Inc.;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Announced the receipt of a Notice of Allowance by the U.S. Patent and Trademark Office for a composition of matter patent application for RDX227675, providing important intellectual property protection for RDX227675
through 2035; and, </TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Subsequent to the second quarter, completed a private placement of common stock in July 2016, with gross proceeds totaling approximately $110 million, providing for a <I>pro forma</I> cash and cash equivalents of $257
million as of June&nbsp;30, 2016, after accounting for the proceeds of the offering. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Upcoming Clinical Milestones </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The expected initiation of both an onset-of-action clinical trial and a Phase 3 clinical trial for RDX227675, for the treatment of hyperkalemia, in 4Q 2016; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">An IND filing expected in 4Q 2016 for RDX98940, Ardelyx&#146;s lead product candidate in its TGR5 agonist program; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Receipt of results currently expected in the first half of 2017 from the RDX227675 onset-of-action trial; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Receipt of results currently expected during 1Q 2017 from the ongoing Phase 3 trial of tenapanor for the treatment of hyperphosphatemia in ESRD patients on dialysis; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Initiation of the second Phase 3 trial of tenapanor for the treatment of hyperphosphatemia in ESRD patients on dialysis currently expected during 1H 2017; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Receipt of results from T3MPO-1, currently expected in mid-2017, for the ongoing 12-week tenapanor IBS-C Phase 3 trial; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Receipt of results from T3MPO-2, currently expected by the end of 2017 for the ongoing 6-month tenapanor IBS-C Phase 3 trial. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Second Quarter Ended June&nbsp;30, 2016 Financial Results </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Net loss for the second quarter of 2016 was $28.6 million, or $0.83 per basic and diluted share, compared to a net income of $9.0 million, or $0.43 per basic
and $0.42 diluted share for the second quarter of 2015. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Total revenue is comprised of licensing revenue and collaborative development revenue. Licensing
revenue for the second quarter of 2016 decreased to zero from $17.7 million for the second quarter of 2015. Licensing revenue for the three months ended June&nbsp;30, 2015 was related to the recognition of revenue from upfront and milestone payments
received from AstraZeneca. As the Company&#146;s collaboration agreement with AstraZeneca was terminated in June 2015, there was no further recognition of revenue related to the upfront and milestone payments after the six-month period ended
June&nbsp;30, 2015. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Collaborative development revenue is comprised of development expenses that were reimbursable to Ardelyx by AstraZeneca.
Collaborative development revenue for the second quarter of 2016 decreased to zero from $0.4 million for the second quarter of 2015. The decrease was due to the termination of the AstraZeneca agreement in June 2015 and related cessation of
reimbursement of research and development expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research and development expense for the second quarter of 2016 increased to $23.8 million from $6.2
million for the second quarter of 2015. The increase was due to expenses incurred primarily for clinical development activities as well as clinical manufacturing and process development activities associated with tenapanor, RDX227675 and RDX98940.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 2 of 6 Pages </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">General and administrative expense was $4.9 million for the second quarter of 2016 as compared to $2.9 million
for second quarter of 2015. The increase was primarily due to an increase in professional services fees including fees for market research and pre-commercialization activities, systems implementation and intellectual property management, as well as
an increase in personnel-related expenses and facility costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B></B>Accounting for the net proceeds from the Company&#146;s private placement in July
2016, the Company&#146;s <B></B><I>pro forma</I><B></B> cash and cash equivalents as of June&nbsp;30, 2016 were approximately $257 million including $146.7 million in cash and cash equivalents as of June&nbsp;30, 2016 plus gross proceeds from the
private placement completed in July 2016 of approximately $110 million. Cash and cash equivalents were $146.7 million as of June&nbsp;30, 2016 compared with $107.0 million as of December&nbsp;31, 2015 primarily as a result of the completion of an
underwritten public offering of common stock in January 2016 that yielded approximately $80.8 million in net proceeds, offset by $41.1 million in cash required for operating and other activities for the period of December&nbsp;31, 2015 through
June&nbsp;30, 2016. <B> </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Conference Call&nbsp;&amp; Webcast Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ardelyx management will host a live conference call and webcast today at 4:30 p.m. Eastern Time&nbsp;to discuss the second quarter financial results. The live
webcast and a replay may be accessed by visiting the investor relations section of the Ardelyx website at ir.ardelyx.com. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Please connect to the
Company&#146;s website at least 15 minutes prior to the live webcast to ensure adequate time for any software download that may be needed to access the webcast. Alternatively, please call 1-855-296-9612 (US) or 920-663-6277 (International) to listen
to the live conference call. The conference ID number for the live call is 56269341. Please dial in approximately 10 minutes prior to the call. An archived webcast replay will be available on the Company&#146;s website until August&nbsp;22, 2016.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Ardelyx, Inc. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ardelyx is a clinical-stage
biopharmaceutical company focused on the discovery, development and commercialization of innovative, minimally-systemic, small molecule therapeutics that work exclusively in the gastrointestinal (GI) tract to treat GI and cardio-renal diseases.
Ardelyx has developed a proprietary drug discovery and design platform enabling it, in a rapid and cost-efficient manner, to discover and design novel drug candidates. Utilizing this platform, Ardelyx has discovered and designed tenapanor, which it
is evaluating for the treatment of irritable bowel syndrome with constipation (IBS-C) and for the treatment of hyperphosphatemia in patients with end-stage renal disease (ESRD) on dialysis. In addition to tenapanor, Ardelyx is developing RDX227675,
a non-absorbed polymer for the treatment of hyperkalemia, or high potassium, a problem prevalent in patients with kidney and heart disease. Ardelyx is also advancing several research programs focused in GI and cardio-renal diseases. Ardelyx is
located in Fremont, California. For more information, please visit Ardelyx&#146;s website at www.ardelyx.com. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the extent that statements contained in this press release are not descriptions of historical facts regarding Ardelyx, they are forward-looking statements
reflecting the current beliefs and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 3 of 6 Pages </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">expectations of management made pursuant to the safe harbor of the Private Securities Reform Act of 1995,
including the potential of tenapanor in the treatment of IBS-C, the expected timing for the receipt of the results from Ardelyx&#146;s two on-going Phase 3 clinical trials evaluating tenapanor for the treatment of IBS-C, the potential for tenapanor
in treating hyperphosphatemia in ESRD patients on dialysis, the expected timing of the results of the ongoing Phase 3 clinical trial evaluating tenapanor for the treatment of hyperphosphatemia in ESRD patients on dialysis, the expected timing of the
initiation of the second Phase 3 clinical trial evaluating tenapanor for the treatment of hyperphosphatemia, the potential for RDX227675 in treating hyperkalemia in CKD patients, the expected timing of the initiation of the onset-of-action and Phase
3 clinical trials evaluating RDX227675 in treating hyperkalemia in CKD patients and the expected timing of the results of the onset-of-action clinical trial, the expected timing for the filing of an investigational new drug (IND) application for
RDX98940 and the potential of Ardelyx&#146;s drug discovery and design platform. Such forward-looking statements involve substantial risks and uncertainties that could cause the development of tenapanor, RDX227675, or Ardelyx&#146;s future results,
performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in research and the clinical development process
and the uncertainties in the manufacture of clinical trial material, including process development, and scale up. Ardelyx undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and
uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Ardelyx&#146;s business in general, please refer to Ardelyx&#146;s Quarterly Report on Form 10-Q filed
with the Securities and Exchange Commission on August&nbsp;8, 2016, and its future current and periodic reports to be filed with the Securities and Exchange Commission. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 4 of 6 Pages </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Ardelyx, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Condensed Balance Sheets </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(In thousands) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,<BR>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(Unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">146,669</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">107,004</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,827</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,711</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid and other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,883</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,231</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total Assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">155,379</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">116,946</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities and stockholders&#146; equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable and accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,061</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,723</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">713</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">322</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">140,605</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">108,901</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities and stockholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">155,379</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">116,946</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Derived from the audited financial statements included on Form 10-K for the year ended December&nbsp;31, 2015. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 5 of 6 Pages </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Ardelyx, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Condensed Statements of Operations and Comprehensive (Loss) Income </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(In thousands, except share and per share amounts) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="62%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three Months Ended June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six Months Ended June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(Unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(Unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(Unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(Unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Revenues:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Licensing revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,727</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21,611</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Collaborative development revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">416</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,415</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenues</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,143</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating expenses:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,838</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,198</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,091</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,396</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,852</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,889</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,130</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,064</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,690</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,087</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52,221</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,460</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>(Loss) income from operations</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(28,690</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,056</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(52,221</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,566</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(49</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">139</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(61</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Provision for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net (loss) income and comprehensive (loss) income</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(28,613</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,007</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(52,082</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,505</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Basic net income (loss) per common share</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.83</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.53</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Diluted net income (loss) per common share</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.83</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.53</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Shares used in computing basic net (loss) income per share</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,636,559</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,880,235</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,051,785</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,749,778</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Shares used in computing diluted net (loss) income per share</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,636,559</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,636,487</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,051,785</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,506,916</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Investor and Media Contact: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Mark Kaufmann </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Chief Financial
Officer </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">mkaufmann@ardelyx.com </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">510-745-1751 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For Investors: </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Bill Slattery, Jr. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Burns
McClellan on behalf of Ardelyx Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">bslattery@burnsmc.com </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">212-213-0006 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SOURCE Ardelyx,
Inc. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 6 of 6 Pages </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g208065g77r46.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g208065g77r46.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M)7LI1:2E9:)M.S[V78^=XCHT_J3:BE)??M^EOQ/SN_83N[BV_: M(H2XCO\
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MER_YN^A\[+B>,9/E@K+:[?Z61BC_ (*F:Q_T1S3QU_YFVXX_\I%:?\0MJ_\
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MTB=])UK2[F$LKZ3KFGW$)'5'L-4ADC8=MP: 8![XK^GL1/\ X381W4,/JO\
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M0=I16'2N?$99F&15L+7Q=+V/+.,HV?\ +[UME;1/\C2.*I9AAZE*A[ZLU?\
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M-%&^8.=^7WUI\T?UG:5_R#--]M.L_P!+:.OY:K:8B7E*?YL_5:?^[P_PQ_\
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MN/56.!=.HJ3M44FDU9M?#*SW\NW=%U\NJ86-.<J<E?5.SZI-:]K&C\(_C_\
M%;X)7ZW7@#Q/=6>G-*);[PS?[]0\,Z@HY*S:5.1'%,.09K8Q3(.=Q'%<N;<-
M8#/(OVF$A&5G:<=&KK=26WY=S7"9MCL,U&E+EC'=/LO)GZ\_ [_@H7\-?'YL
M]#^(T$7PS\4R^7"MU<S//X.U*X;*YMM59=^D;FQMBO\   _Y;,.:_'\[X!QF
M5WJ8=/$TX_R)\\?DO=E\N5^3/M,!Q!A\4E%KV<O-Z?\  _$^[]5N;>\\-:O=
M6EQ#=VL^AZA+:W5M+'/;7$#V$S1RP31,R2QLI!#*2",$$YKX^A"K2Q%.%5.+
MC4@K---:J]T[-/U/7K3C+#5FFG>$K6:?V6?RAVW&LV_;&NP^V,:JM?U#5:_L
MK#=EAY?^D,_,(Z8SM[Z_-']9VE<:9IO;_B76?MTMHZ_ENLTL1+6WO3_]*9^I
MTU^X@NT8Z?)&A[>E9<R511NE[NB*E&\4MK'RW^V%\4[#X5? GQK>R7<46M>)
M]-NO!_AFT9U\Z[U36X);.9H8\Y=+:PDNKF0@?*(!W(KZ+A/*ZF89SAH*+]E2
MJQG-VT44[Q^]K3R3['EYOBUAL'-77-*+BE?7ST6Z2T?J?@?\ O!\_CCXS?"_
MPG;1M*+WQ=H\UQ@%O+L-)F&K7TSX_A2UL)6.>..>*_>L]QT<MX>Q<I>[RS=-
M=&UJE;N?G^ I2Q%=\OQ]%Y^GX' ^,)IY_%'BVYNVD\^;Q)XBEN"?E<S/JEV\
MR[F'$F<D'!''(KNP'[W+:*IKEIPH+79-VO?SN<TXR6)Y9=);?/L?U'?"BST.
MR^&GP\M?#L5M'HD'@SPU_9:VNTP_8WTFUEB>-E^\&WERW4L[$\DU_,.:MSS?
M'*M?VD:M5I-NVDY)>MDDEY6/U3 >SA@Z"BM.6-M/+7\;GHF?\YKCO/\ D7WH
MZ[>6WD&<?A_2AN:7PI6Z706MTV.5\;Z'_P )-X-\6>'-H+:]X:UO1D!.!YFH
MZ9<VD?)Z 22H?3BM\%7G0Q.'K<JBZ-2$D[K[,DSGQ4/:8>M3MI*$EMUMI^)_
M*=9OJ/A;6K26)6@UCPOK,$BJYV[-0T2^0;6/_+/_ $NT"9/09XK^J)1CF-"%
M+_EW7P:;?V;\O?:_D?E[_P!EQ\>G*S^I+X0?$W0/B]\//#?CSP[<QSVNLV$3
M7D".C2Z;JT*+%JFEW:*Q,-S;7BRQE6Y("L/E8$_S%F>!J9;C<1A:D7'V<WRM
MIJ\;^[)7\K?,_3L'7C7P].HGTL_5;_Y^AZ7GCM^'M7G-JVZT.FWX#?Z#\NW\
MLTX-='LP:M'T/Y\O^"@7'[3OBK_L6_!OZ:)'C]*_=_#[_DG9V_Y^U/\ TH_.
M>)-,;+I[L?R/TF_X)U\?LU:1VQXO\8^V,:F*_.N/=.(:O2U.G_[<?5<._P#(
MOC_B?Y1/NKI[?ITKX[;R/<_0_,__ (*,?&W_ (17P78_!_0KLQZYX\C%]XC:
M&0*]EX0M)BGV9V4YC;4K^)8L<9@MK@?\M!7Z'X?Y,L5C_P"U*L+T,#M=:.76
MWHG;3JWV/EN),R>#HQI4W[T[7MVZ7_KL?G1^R3\&G^-/QCT+2+V#S?"?AEH?
M%/C!R@,+Z9I\^ZSTN3CA]1O1#!LY_="X;HN!]]Q;GW]EY;C*E*T98M*G2CV<
MM+I=HK7Y'SF3X/ZUCJ$I1?))2<ONOZ>A]G?\%(O@FL2>'_C=H-GM2);3PGXT
M2V4*J0 ,OAS6) !\JQD26$C]E^RJ.M?(^'^?5*,Z^45I*U=N<&W;K[RU\VG\
MWV/;XAP$:5*%6$+<NCLMK;=.R];IMGSQ^PA\;?\ A5WQ9B\*:S=^1X0^)+VV
MBW9F<+!IWB6-G70M4)8A8Q-,[V,I'_/W&6)$(->_Q[E$<;E].O2IWKT$Y:+5
MQ^TOFE=>:1YV18YPK1I2=H;?\'Y/\+H_?Y>,#CCMZ8K\+@N5.-[\K_X8_05J
MD]K?GL.JAGQK^W+\*K[XI_ C6HM%M7N_$'@R[M_&.E6T*;[BZCTQ)8M6LH0.
M?,DTJ>YD55Y9[5!7TO!F:1P&=49U7R4Y-0DWHM[Q;OTOIZM'C9YA'B\+RQ^S
MJE^#_3[GV/P)^'_C_P 5_#+Q7I7C;P5JTNC>(-*EDDM;J.,20RQ3*L5U97=I
M*!%=6,T9,<L#@A_,R K0HP_?LRRREGV"G&JU.C-72\MU;LUNFMF? 86M5RVH
M[7BX.R^1]PK_ ,%+_CJ(U23PW\.GD"!6D.G:N 6"$%]G]ICJV#@$#MTKXJ'A
MAE$H2FZLU.+NES1_^1O?S/<CQ35Y6K+1=CXO^)WQ1\9_%[Q9=^-?'FKG5-9N
M(8[>)%B%O8Z;81;S%INF6B%DM;2)I)7\L$[O,+R.S<C[;)<FP^3X+V%#EI4X
M_B^K;W;?5L^?QN/KX^;WD_\ +96\NG8_:?\ X)V?"Z_\#?!F[\5ZO:R6FH_$
MW5DURVAGC\NX7P_86WV+19)$8[HQ<@W5VJD#]W.C?QBOP[CS,H9AFCITI<RP
MON-K;GOK_P" I*_FS[[A["RPN'3DK.:3^5OUO^!PG_!3GX?G5/A[X(^(MM"O
MVGPCXADT+4I50LPT?Q+$# TC#I!%JUC;#'=KM17J^&^81P^98C!3=EBZ:Y?\
M4-_O5ON,.(\.ZM*G42^!M?*UU^-SX[_X)^^/?^$5^,FJ^%IYA'I_Q#\':SI*
MH[X0:OI5M/J^F<=-[QI>P*>I,R@=:^PX_P #/$X3+L3"/,L)5C=]ESI/[E^1
MX.1XI4:TJ;>CC*-OD[?C;[CXD;C6&QT&MMC'MJ;8KZZULLQJ[4?_ &U'EW_V
MQ?XW^9_5B_A_1O$_A&RT/Q#I.FZWH][HUA%>:;JUG!?65PC642D/;W",N0"V
M& W*3E2"*_F%UZV&Q$JM"3A.,Y-.+L]):>OH].Y^FPI*KA:,&DTX1NFNG)'[
MOD?FM\<O^";>AZJ+S7_@?J:>'-18R3OX+UN>6;0;B0!V6+2-599)]())P$G%
MQ$,X#1J!C] R+Q&KX=1P^8+VM.-ESQTDDM^:.S]8_<?/8[ARF[U*#]Y]'I^.
MR^=C\G?'GPX\<?#'69?#OC_PQJGAC4D+!$U*W*VEY&AP9]-OUS;ZE;GJ'MY'
M'8E3Q7[#EN9Y;FU+_A/QD:T6M8-J^VJ:>J^9\E5P.*H2UIN/+Y6/>?V8/CE\
M4/ _CCPOX#T3Q1>'P9XJUB+1-5\,:HS:GI26VI130S3Z;#<,'TJZ .Y6MC&F
M0 T;@$5\_P 1\/Y36PL\55PRHXFA./+..CEJGNEJM%O='=E^95J//2;:4M+?
M)K;YGRX[FVU"66, FVU*6>,/\P+07K2Q[P,<,47<!MZG&.,?24:,<5@\-AZ7
MNT_9.-MM.5H\RK-_7'4_E=UZK5'Z#P?\%+OCA;00P)X5^'FV"*.%&:TU@LZQ
M)'&C,%U( ,54]#BOS^OX:9=*;<:M2UV_B3M?M[NB/<AQ+CHVT5DDOA738)_^
M"E_QVEB>./PW\.[=V&$F_LW5IC$?[XA?5=LC#@@,0.*(^&>3^[[6K4<ULN9;
M+_MVZ^5C5\4XB,;223>WNK\CX[^*GQB^(OQFUT>(OB)X@GUBZMH7AT^SCC2T
MT?2+9WW-%IFFPGR+-6(&^1@TCD!G9L?+];E7#^ R&C45*T$TVWU=EU;U;MW/
M!Q>8XG&U(NSE9K\S],?^"<G[/^H:6]Y\>/%>GRVGV_3IM&^']K=1F.9K&[D_
MXG'B18W 9(;A%%K;,P!:(SE<K(,_FGB%Q#2Q4<-EF&ESQH-.I;9?RQOW^T^J
M27<^KX<RN4)5,957+*2]U/OWMY?GZ'PY^UY\*K_X4_';QG82VDD&A>)]2N_&
M'A>Z,;_9KC2]9GDNKBV@?;M:6SU)KJW= <KMCR/G7/WO!>;QS3*L-AW4494(
M>RG'1/FCY>>Z\FCP<VP-7#8ZI42]W=-=OZ_R.E^$7[;OQI^#GA6U\%Z2WA_Q
M+X>TS<NC6_B:SN;BZTB!V,GV*UO;2[@<V,;L^R&02>7NPC!3M7BS?@'*\=C)
MUZDI0E+63@]WT;5G=KH]'T=TD;83B'$8:'LE]G:ZO:WKMZ'JW_#S3XYC_F5?
MAV,?]..LC_W*UYG_ !#7)U_S%5]/)?\ R)U_ZS8SM'_P%!_P\T^.8_YE7X=C
M'_3EK(QCV_M6B7AEE;BN2O5DK_::7X<I5/B3&.;NHV2VY4CW']F[]NCXK?%[
MXS>$/AYXD\/^"['1M?;5Q>7.DVVIQZA";'1[N_A%NUQ>R1A7GMT#[E)VGBO!
MXBX'P>3Y?5Q5.<Y3HPYHJ336Z79'=EF=8K&XF-&=E"3L[)+0^;_V]/V?=2^&
MGQ+O_B/HMA(W@/XA7S7\EQ!$6M]"\5W!WZEIUXT:XMDO92UW;LVU',LD:Y>,
MBOI/#WB#Z[0_LK&U5%4(KEYG9M+1/]'Y^IYF?Y;.%;V]*+<=UY>7]=#YD^$O
MQU^)_P $M2GO_AWXFGTJ._9'U+1KB*+4=#U,QC"O>Z7<9CWB(#%S"R2X.%?%
M?49OPOEN<1;K)2G%VBUHU;9IK7;S]3R,+F^-PFD+QC'2W_ /K2W_ ."F'QWC
MB19?#OP[GD51NE.F:M!O..<1IJA"@GGK7R,?#'+[V=6HD]O>7_R)[2XGQO+L
MKK^ZB0_\%-/CGC_D5?AV, D8LM9&,#WU,\$=>.G2I_XAIEU*$Y>UJ>[VDE^4
M28<3XV<N2T8_)'SW^TMXTU/XC?$+1O'NLP6=KJWBSX:^ -9U"WT]94LH;FXT
M=E>.U69WD6$"-<!V)]:]SA/!T\OP.,P=)MPH5YQ3;N]'Z(\O-:]3$356K\<E
M&]O2RT/UU_X)V\?LU:3[>+_&/Z:F*_+./XI\1UELO94_PYC[;AS_ )%\/\4O
MRB?9/B;Q#I7A/0=7\2ZY<I9:-H.G7FK:E>2$!+>SL8'N)FY(RY6/"*,EF*J!
M\U?(8>A4Q>)I8:E'FE.48Q7]Y[?);OR1ZM2M'#TZDY.RBFWZ+_/9>;/YB_C'
M\3-4^+WQ(\5?$+5RZ'6[]_[+M"S,NF:':!HM%T^$$G AL84)4* TLDKGEN?Z
M2X;RVGD^7X?!5-(.#E4?F];GYCCJSQ^+GRZIM67II^!^X/[#?P5_X5/\'[#5
MM5M!;^+_ (A_9_$^M>:FVYL].E@ T#2&)&Y/(L76=TX FO)>,BOQ/C'.?[3S
MBKAZ<N;#8)N$+;:2M)]GM:_9,^]R;!?5,)%VM.2O\NGW[_<?47CSP;H_Q!\'
M>(_!&OPB;2/$VE7>E7BD!GB%Q$PANH=PPMQ;SB*>-OX9(4/:OGL)BJF#QE#$
M4M)4)*2^3V^:T/1Q%+ZUAJE*5ES)K^O3?\#^8'Q]X+USX9^./$G@?6M]KK?A
M/6)]/^T1>9$TC6T@DL-2MG[)<6YM[F)Q_P ]5P<BOZ2R_'4LZP."KP::JTK3
M\MUJC\NKTIY?B94VK*G*Q_05^R)\:4^-GPBT36+Z=7\6>' GAGQ?%TE.J6$$
M?V?4W4G=LU"Q,%R&Z&1Y@/N\?@W%>2RR/.:U*G'_ &;$-U(M;)=O^W7IIT<3
M]"RG'+$X6$;^]&R?RV?X:^?J?4]?.GK$31!@0QR"""I (P>#PP(P02"#U!(H
MNTTXOE:ZH;LU:VQ^:_QU_P""=7A'Q_KFH>+/AIX@B^'^L:G<276I:%<:>;_P
MM=7DK%YKJR@MW2?19)7+&181)&2Y*J@+*_WV2\=9AEM*.'KTUB*44HJ7,U+E
M2LKW:4GYZ/O=GS>,X?AB'*<)<KDV[6_+_@_>?,?_  [%^+X; \>?#YER0&QK
MBYQT( L6QQSCFOIX^)N!A3M]4FY=KK]9'D2X6J_"IV7?0]^^#W_!-;PUX8UF
MSUWXL>*8O&[6$L-S;^%](LI=.\/W$T+K*JZO/=R/<ZG:+(JYMT2!6(!<D?*?
MGLY\0,9CZ#H8*@L+%Z<ZE[WR2;2]6_D>C@.&X85J52?/;I;\W_E?U/U!M[2"
MTBA@MHH[>""**&"WAC2*""&&,110PQ( L42(J*JJ  $4 8%?G<G.<^><G)ZM
MWUU>K;;W;;;;/IX05-))6Y4E]VAY?\<OAO%\6_A3XT^'3S6]M/XFT::TL+NZ
M5F@LM4@>.\TV]E$8+!(;VW@8E02!TKORG,EE&:83'ZOV,O@Z25K-?<S#%X=X
MJA.DM+[>3_JZ^9^6'@[_ ()U?'+P7XJ\-^*].\=_#]=0\/:M9:I"4;7%W/!)
MOFBYL/NM$TB>X;FOU#$>(N7XK!/"U\$[.7-S.S\[:O8^1I<.8FA6=2$[Z[.R
M_4QG_P""9GQB:_:\_P"$U^'R(VHF]* ZY\B->?:3&#]AZA25'N!4R\1L&\+7
MH4L-*3K0Y;OII;HWV-%PY656-1U+6=[:'[9:9 UK86-JY!>TLK6W=ER%9X($
MB8KG!VDH2,@<&OR2HY2J3:]V+DVOF[V^1]C2BZ5*$/Y8I?<DOT+I3/<C_P"M
M[5'+#^1,J/NWO[WJ<;XU^'?@OXB:'/X=\<>'-)\3:/.#FTU2TCG\AR,>?9S$
M>;97*\$30/&X(^]75@\7BLNJPJX&M+"N.ZBW9^35]48UL/0K1<94TD_Z_K\3
M\Z[[_@G7:>%?BIX/\;_"_P 7+:>&M'\0VNKZCX:\4K/<W=E!;LQ\C1]7M8\W
M47S[4CNT#C@&9L$U][2\09U<#+!9K252:<7"I%V>F]TW:[/F\1P^HUHU</)R
M6MTTM.VO4\ E_P""9'QCDFGE7QO\/@LL\TJC.N$A7E=U!_T#J 1FOH:7B;EE
M.%*$<-.'LER^[RZ_^3'%4X;Q$Y\_-R^6A&/^"8GQE'_,\?#[C_L._P#R#6J\
M3LL7_,+5_P#)?_DB/]6<1_/:W^$L6W_!,+XMO,B77Q \ VL)(W2Q0:[<R*,X
M.V'[+&&('3,BUG/Q.R]-.&!G*45IS.*_]N''AB>BJ5&NVVQ]2?"#_@G%\,O!
M5_9ZY\0]:NOB3J=G(D]OI,MG'I7A6.9,%6N-.626XU,!@&V3SK&2OS1M7R6<
M\>9AF*<,-1CA(2T;4G*5O+[*>W<]G!Y!AL/9RDZCC9VM9:?C^7J?HM!:0VL4
M5O;1QV]O!&D,%O#&D4,$,:A(XH8HP%BC1%"JJ@!1P!7PKE*4W.<G)O775W[M
MO5M]6SWE!1BHP7(EVT/'_C5\!_A]\=_#*^&O'.G/(UI))<:)K=BR6^M:#>S+
MLDN=.N61@$D  FMY%>*50-ZY567T<IS;'9/B?;X6?NMIR@VU%VZ:/3R?3S6A
MRXO!TL7#EG[K2LFEK_7]7/R^\1?\$O/'=O>RCPG\3/#.I::9&\@^(-,U+3M0
M2($[!<&Q^TPRR!=H+)L!()P*_3<)XFT8Q7UK!M5%97C)2^:NUMYH^8J<,I2?
MLZC=_)*S^9SX_P""8GQE_P"AW^'PQ_V'1T_[<*[?^(H8+_GQ4T_N0_S.?_5C
M$K_EY:WI_F'_  [$^,@_YGCX?<>^N]O^W&HEXGX"ZO0F[=&HK\%(/]5\3?\
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MI-+DTY;JS=^]CY_ <.?59QE*K*:3N]%W_JQ^PD<*QJJIA54855 554=%"C@
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5=M BVFUV%  [=/Z4GNO(;8Z@1__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
